PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition

PROVECTUS BIOPHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $305.94 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital

us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13

• PROVECTUS BIOPHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $305.94K, a 5.01% decline year-over-year.
• PROVECTUS BIOPHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $306.05K, a 2.87% decline year-over-year.
• PROVECTUS BIOPHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $322.07K.
• PROVECTUS BIOPHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $315.10K.
• PROVECTUS BIOPHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $1.28M.
• PROVECTUS BIOPHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2020 was $64.29K.